IN RE: GENENTECH, INC., Herceptin (Trastuzumab) Marketing and Sales Practices Litigation.
United States District Court, N.D. Oklahoma.https://leagle.com/images/logo.png
Signed March 20, 2019.
Signed March 20, 2019.
Editors Note
Cause: No cause code entered Source: PACER
Attorney(s) appearing for the Case
Tulsa Cancer Institute, PLLC, an Oklahoma Professional Limited Liability Company, Oklahoma Oncology & Hematology, Inc., an Oklahoma Corporation doing business as Cancer Care Associates, State of Oklahoma & Texas Oncology, P.A., a Texas Professional Association, Plaintiffs, represented by Adam C. Doverspike , Gable & Gotwals, Amelia Ann Fogleman , Gable & Gotwals, David Len Bryant , Gable & Gotwals, James Wesley Scott Pebsworth , Gable & Gotwals & Steven Joseph Adams , Gable & Gotwals.
Oncology-Hematology Associates of Central Illinois P.C., Plaintiff, represented by Adam C. Doverspike , Gable & Gotwals & Janaki Hannah Nair , Elias Meginnes Riffle & Seghetti.
Before the Court is the Amended Motion for Summary Judgment Based on Federal Preemption (Doc. 201) filed by defendant Genentech, Inc. ("Genentech"). Plaintiffs oppose the motion.
I. Introduction
Genentech manufactures, markets and...
Let's get started
Welcome to the leading source of independent legal reporting Sign on now to see your case. Or view more than 10 million decisions and orders.
Updated daily.
Uncompromising quality.
Complete, Accurate, Current.
Listed below are the cases that are cited in this Featured Case. Click the citation to see the full
text of the cited case. Citations are also linked in the body of the Featured Case.
Cited Cases
No Cases Found
Listed below are those cases in which this Featured Case is cited. Click on the case name to see the
full text of the citing case.